| Exclusion Criteria: | 1) Primary cutaneous anaplastic large cell lymphoma
2) Lymphomatoid papulosis
3) Histopathological evidence of sheets of large cells (from skin or nodes) or poorly differentiated tumors.
4) Prior treatment with Total Skin Electron Beam (TSEB) therapy within 6 months.
5) Prior treatment with Campath (alemtuzumab)
6) Prior treatment with more than three regimens of single agent chemotherapy
7) Prior treatment with pentostatin within 6 months.
8) Treatment within 4 weeks prior to visit 2 with topical Targretin®, skin directed therapies or systemic anticancer therapies, such as, but not limited to: Targretin® , UV-light therapy, local Electron Beam Therapy (EBT), extracorporal photo chemotherapy, methotrexate, bleomycin, cyclophosphamide, combination chemotherapy, oral retinoids, systemic glucocorticosteroids14, carmustine, nitrogen mustard, systemic vitamin A or etretinate
9) Treatment with topical glucocorticosterioids within 2 weeks prior to visit 2
10) Unwillingness or inability to avoid prolonged exposure to the sun or UV light sufficient to produce a mild erythema or thought by the investigator to likely modify the patient's disease
11) Concurrent or previous malignancies within the past five years except adequately treated in situ carcinoma of the uterine cervix or basal or squamous cell skin carcinoma
12) Acute or chronic infectious disease requiring medication. Patients with a history of intermittent relapsing herpes simplex skin affection on prophylactic treatment with acyclovir or valacyclovir and patients taking dicloxillin for carriage of staphylococcus aureus may be included.
13) Significant concurrent, uncontrolled, or active medical condition including, but not limited to renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, cerebral or psychiatric disease
14) Screening blood laboratory values: hemoglobin < 8.5 g/dL, WBC </= 2.5 x 10(9) cells/L, platelets < 100 x 10(9) cells/L, ALT/AST > 3 times upper limit of normal, S-Creatinine > 1.5 mg/dL, CD3(+)CD4(+) cell count > 10000 cells/mm(3).
15) Known or positive serology for HIV
16) Known or positive serology for hepatitis B or C
17) Signs or symptoms of CNS involvement
18) Patients who are currently participating in any other trials or having received treatment with any experimental agent within 4 weeks prior to visit 1 (screening)
19) Prior treatment with anti-CD4 monoclonal antibodies
20) Patients known or suspected of not being able to comply with a study protocol (e.g. due to alcoholism, drug dependency or psychological disorder)
21) Breast feeding women or women with a positive pregnancy test at Visit 1
22) Women of childbearing potential not willing to use either hormonal birth control, an intrauterine device or double-barrier method for the entire study period |